Abuse Potential Assessment of Cebranopadol, a Novel Dual Nociceptin (NOP) and Mu Opioid (MOP) Receptor (NMR) Agonist: Implications for Scheduling (CPDD 2025) - Jun 9, 2025 - Abstract #S83; Pres time: Jun 15, 2025; 05:00 PM - 06:30 PM; Location: Napoleon Ballroom CD, Third Floor; " In the drug discrimination procedure, cebranopadol showed dose-dependent generalization to morphine; however, effects were antagonized by naloxone (MOP antagonist) and enhanced by J-11397 (NOP antagonist), indicating NOP activity reduces its MOP agonist properties...In recreational opioid users, cebranopadol at doses up to 2.5 times the anticipated maximum therapeutic dose showed lower abuse potential compared with Schedule II (hydromorphone, oxycodone) and Schedule IV (tramadol) opioids... The overall abuse potential of cebranopadol is less than Schedule II and IV full and partial MOP agonists, suggesting a less restrictive schedule than Schedule II is appropriate."
Addiction (Opioid and Alcohol) • CNS Disorders • Depression • Pain • Psychiatry
|
|
Megan Shram; Glen Apseloff; Joseph Grieco; David Fam; Marc Lesnick; James Hackworth
|